These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2414666)

  • 21. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    Schoser B; Eymard B; Datt J; Mantegazza R
    J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
    Sakai W; Nakane S; Matsuo H
    Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor.
    Newsom-Davis J; Murray N; Wray D; Lang B; Prior C; Gwilt M; Vincent A
    Muscle Nerve; 1982; 5(9S):S17-20. PubMed ID: 6302493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive transfer of Lambert-Eaton myasthenic syndrome induces dihydropyridine sensitivity of ICa in mouse motor nerve terminals.
    Xu YF; Hewett SJ; Atchison WD
    J Neurophysiol; 1998 Sep; 80(3):1056-69. PubMed ID: 9744921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse.
    Waterman SA; Lang B; Newsom-Davis J
    Ann Neurol; 1997 Aug; 42(2):147-56. PubMed ID: 9266723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
    Mason WP; Graus F; Lang B; Honnorat J; Delattre JY; Valldeoriola F; Antoine JC; Rosenblum MK; Rosenfeld MR; Newsom-Davis J; Posner JB; Dalmau J
    Brain; 1997 Aug; 120 ( Pt 8)():1279-300. PubMed ID: 9278623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
    Kitanosono H; Shiraishi H; Motomura M
    Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
    Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse.
    Lang B; Newsom-Davis J; Prior C; Wray D
    J Physiol; 1983 Nov; 344():335-45. PubMed ID: 6655585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].
    Shipley E; Krim E; Deminière C; Lagueny A
    Rev Neurol (Paris); 2008 Jan; 164(1):72-6. PubMed ID: 18342060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate.
    Fukuoka T; Engel AG; Lang B; Newsom-Davis J; Vincent A
    Ann Neurol; 1987 Aug; 22(2):200-11. PubMed ID: 3310854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Muscle Nerve; 2005 Apr; 31(4):487-94. PubMed ID: 15685615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
    Takamori M
    Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones.
    Fukuoka T; Engel AG; Lang B; Newsom-Davis J; Prior C; Wray DW
    Ann Neurol; 1987 Aug; 22(2):193-9. PubMed ID: 3662451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lambert-Eaton myasthenic syndrome].
    Motomura M; Fukuda T
    Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lambert-Eaton myasthenic syndrome (LEMS)].
    Suzuki S
    Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lambert-Eaton syndrome antibodies inhibit acetylcholine release and P/Q-type Ca2+ channels in electric ray nerve endings.
    Satoh Y; Hirashima N; Tokumaru H; Takahashi MP; Kang J; Viglione MP; Kim YI; Kirino Y
    J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):427-38. PubMed ID: 9508807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome.
    Morris CS; Esiri MM; Marx A; Newsom-Davis J
    Am J Pathol; 1992 Apr; 140(4):839-45. PubMed ID: 1314026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.